in which they proposed to stratify patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) post interferon alpha failure treated with imatinib mesylate into different risk groups. In a multivariate analysis of 145 patients, they identified low neutrophil counts o10 9 /l 6-12 weeks into therapy and a poor cytogenetic response (Ph-positive cells 465%) at 3 months to be independent poor prognostic factors. Each factor was assigned a score of 1. Patients were then divided into three risk groups: low (score 0; 35%), intermediate (score 1; 36%), and high (score 2; 29%). The estimated 2-year survival rates were 100, 82, and 40%, respectively (Po0.0001). The estimated 2-year progression-free survival rates were 100, 66, and 15%, respectively (Po0.0001). The risk score was validated in an independent patient population (presumably from the British studies).
Since different study groups may have different prognostically relevant patient and leukemic cell characteristics undetected by study eligibility criteria (latent prognostic variables), we investigated the relevance of the new risk score in our study group of 258 patients with Ph-positive chronic phase CML post interferon alpha failure treated with imatinib. In all, 221 patients were evaluable by the two prognostic factors. Their outcome is shown in the Table 1 below. While a poor cytogenetic response at 3 months was predictive of worse outcome (2-year survival rates 98% vs 85%; Po0.001), survival by neutropenia o10
9 /l at 6-12 weeks gave a paradoxic result (estimated 2-year survival rate of 100% with neutropenia vs 88% without neutropenia; P ¼ 0.006). This was because a subset of patients without neutropenia had a brief period of complete hematologic response before developing resistance and transformation/death from CML. Of note, even the worst risk group in our study (corresponding to the intermediate risk group according to the Marin model) had estimated 2-year progression-free and survival rates of 80% (vs 15 and 40%, respectively, in the study of Marin et al). In a multivariate analysis, we had found prolonged myelosuppression anytime during therapy with imatinib (grade 3-4 neutropenia or thrombocytopenia) to be independently associated with worse response to imatinib.
2 This was most noticeable when myelosuppression lasted 42 weeks.
Our findings highlight the importance of testing in independent populations the score model proposed by Marin et al (as any other model) before it becomes accepted as a basis for therapeutic decision making. 
